Aduro Biotech Inc. (NASDAQ:ADRO) was down 1.6% on Thursday . The stock traded as low as $14.23 and last traded at $14.32, with a volume of 167,841 shares changing hands. The stock had previously closed at $14.56.

Several equities research analysts have weighed in on ADRO shares. Canaccord Genuity reissued a “buy” rating and set a $30.00 price target on shares of Aduro Biotech in a research report on Friday, August 5th. FBR & Co reaffirmed a “buy” rating and issued a $34.00 target price (up from $30.00) on shares of Aduro Biotech in a research report on Saturday, May 14th. Leerink Swann reaffirmed a “buy” rating and issued a $48.00 target price on shares of Aduro Biotech in a research report on Thursday, May 5th. Roth Capital reaffirmed a “buy” rating and issued a $22.00 target price on shares of Aduro Biotech in a research report on Monday, July 11th. Finally, Zacks Investment Research cut shares of Aduro Biotech from a “hold” rating to a “sell” rating in a research report on Monday, July 18th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $22.00.

The firm’s market capitalization is $891.66 million. The stock has a 50-day moving average of $14.38 and a 200 day moving average of $13.22.

Aduro Biotech (NASDAQ:ADRO) last announced its earnings results on Wednesday, August 3rd. The company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.21. The firm earned $39 million during the quarter, compared to the consensus estimate of $25.24 million. The company’s revenue was up 306.3% compared to the same quarter last year. Equities research analysts anticipate that Aduro Biotech Inc. will post ($1.15) earnings per share for the current year.

In other Aduro Biotech news, insider Thomas W. Dubensky sold 25,000 shares of the business’s stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $11.61, for a total value of $290,250.00. Following the completion of the transaction, the insider now directly owns 13,939 shares in the company, valued at $161,831.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

An institutional investor recently raised its position in Aduro Biotech stock. Jennison Associates LLC increased its stake in shares of Aduro Biotech Inc. (NASDAQ:ADRO) by 9.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 855,338 shares of the company’s stock after buying an additional 74,073 shares during the period. Jennison Associates LLC owned approximately 1.35% of Aduro Biotech worth $24,069,000 at the end of the most recent reporting period.

Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.